Ibandronate Sodium Monohydrate (Standard)

Overview

Ibandronate Sodium Monohydrate (BM-210955; RPR-102289A) (Standard) is the analytical standard of Ibandronate Sodium Monohydrate ( HY-B0515 ). This product is intended for research and analytical applications. Ibandronate Sodium Monohydrate (BM-210955; RPR-102289A) is an orally active, selective inhibitor of farnesyl pyrophosphate synthase ( FPP synthase ). Ibandronate Sodium Monohydrate can block the mevalonate pathway to inhibit the isoprenylation modification of small GTPases (such as RAS , RHO family proteins), induce tumor cell apoptosis and inhibit bone resorption. Ibandronate Sodium Monohydrate inhibits tumor cell proliferation (such as ER + breast cancer cells), promotes the expression of the pro-apoptotic gene FAS, and can produce synergistic anti-tumor effects with anti-estrogen compounds. Ibandronate Sodium Monohydrate is used in the study of osteoporosis and bone metastatic tumors (such as breast cancer bone metastasis).

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Breast Cancer | Products > Signaling Pathways > Others | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Signaling Pathways > Reference Standards | Products > Signaling Pathways > Apoptosis

Product Information

• Catalog No.: HY-B0515R
• CAS No.: 138926-19-9
• Molecular Formula: C9H24NNaO8P2
• Molecular Weight: 359.23
• Purity: 95%
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.
• Availability: In-stock

Source

Original product source